Guyasuta Investment Advisors Inc. Has $10,439,000 Position in Allergan PLC (AGN)
Guyasuta Investment Advisors Inc. boosted its position in shares of Allergan PLC (NYSE:AGN) by 577.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 45,328 shares of the company’s stock after buying an additional 38,636 shares during the period. Allergan PLC comprises 1.3% of Guyasuta Investment Advisors Inc.’s investment portfolio, making the stock its 29th largest position. Guyasuta Investment Advisors Inc.’s holdings in Allergan PLC were worth $10,439,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AGN. Veritas Asset Management LLP bought a new position in Allergan PLC during the second quarter worth approximately $492,177,000. Emerald Acquisition Ltd. bought a new position in Allergan PLC during the second quarter worth approximately $231,671,000. Appaloosa LP boosted its position in Allergan PLC by 351.7% in the second quarter. Appaloosa LP now owns 1,260,809 shares of the company’s stock worth $291,360,000 after buying an additional 981,700 shares during the last quarter. Thornburg Investment Management Inc. boosted its position in Allergan PLC by 133.2% in the second quarter. Thornburg Investment Management Inc. now owns 1,717,844 shares of the company’s stock worth $396,977,000 after buying an additional 981,355 shares during the last quarter. Finally, Eaton Vance Management boosted its position in Allergan PLC by 112.8% in the second quarter. Eaton Vance Management now owns 1,713,711 shares of the company’s stock worth $396,021,000 after buying an additional 908,569 shares during the last quarter. Institutional investors and hedge funds own 86.89% of the company’s stock.
Allergan PLC (NYSE:AGN) traded down 1.16% during midday trading on Monday, reaching $189.99. 5,241,734 shares of the company were exchanged. The company has a market capitalization of $71.26 billion, a price-to-earnings ratio of 5.33 and a beta of 1.08. Allergan PLC has a 52-week low of $184.50 and a 52-week high of $322.68. The company has a 50 day moving average of $212.72 and a 200-day moving average of $233.35.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $3.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.65 by $0.33. Allergan PLC had a net margin of 93.74% and a return on equity of 7.26%. The firm earned $3.62 billion during the quarter, compared to analysts’ expectations of $3.73 billion. During the same quarter in the prior year, the firm posted $3.48 EPS. Allergan PLC’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities research analysts anticipate that Allergan PLC will post $13.37 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Shareholders of record on Tuesday, February 28th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.46%. This is a boost from Allergan PLC’s previous quarterly dividend of $0.05.
A number of research analysts have recently commented on AGN shares. Vetr upgraded shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 price target on the stock in a report on Monday, August 1st. Credit Suisse Group AG set a $322.00 price target on shares of Allergan PLC and gave the stock a “hold” rating in a report on Wednesday, August 3rd. Mizuho upped their price target on shares of Allergan PLC from $232.00 to $246.00 and gave the stock a “neutral” rating in a report on Friday, August 5th. JPMorgan Chase & Co. set a $325.00 price target on shares of Allergan PLC and gave the stock a “buy” rating in a report on Friday, August 5th. Finally, Royal Bank Of Canada cut their price target on shares of Allergan PLC from $307.00 to $300.00 and set an “outperform” rating on the stock in a report on Tuesday, August 9th. Seven research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $289.11.
In related news, CEO Brent L. Saunders purchased 5,250 shares of the business’s stock in a transaction dated Monday, November 21st. The stock was acquired at an average price of $189.13 per share, for a total transaction of $992,932.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Maria Teresa Hilado purchased 1,422 shares of the business’s stock in a transaction dated Friday, November 11th. The shares were bought at an average price of $210.64 per share, with a total value of $299,530.08. Following the purchase, the chief financial officer now directly owns 12,659 shares of the company’s stock, valued at $2,666,491.76. The disclosure for this purchase can be found here. 0.27% of the stock is owned by company insiders.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.